Illumina pays $325 million for patent litigation ceasefire with Chinese rival
The limited deal only covers the US, which means the company’s disputes with BGI over gene sequencing technology look set to continue elsewhere
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.